Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study

Chih-Chiang Chiu, Mong-Liang Lu, Ming-Chyi Huang, Po-Yu Chen, Yen-Kuang Lin, Shih-Ku Lin, Chun-Hsin Chen, Chih-Chiang Chiu, Mong-Liang Lu, Ming-Chyi Huang, Po-Yu Chen, Yen-Kuang Lin, Shih-Ku Lin, Chun-Hsin Chen

Abstract

Background: Metformin has been used for alleviating metabolic abnormalities in patients with schizophrenia. The lowest dose of metformin to treat metabolic abnormalities in clozapine-treated patients is 1000 mg/d. This study was designed to determine whether metformin at 500 mg/d and 1000 mg/d is effective in improving the metabolic profiles of clozapine-treated patients with pre-existing metabolic abnormalities, and whether its effectiveness depends on metformin dosage.

Methods: In this 12-week, randomized, double-blind, placebo-controlled trial, metformin at 500 mg/d or 1000 mg/d was prescribed to clozapine-treated patients with schizophrenia who had pre-existing metabolic abnormalities. The recruited patients underwent physical and laboratory evaluations at weeks 4, 8, and 12. The outcomes were any changes in metabolic traits.

Results: Among the 96 clozapine-treated patients with schizophrenia screened for the trial, 55 patients with pre-existing metabolic abnormalities were randomly assigned to placebo (n = 18), metformin dosage at 500 mg/d (n = 18), and metformin dosage at 1000 mg/d (n = 19) groups. The body weight (BW) of patients in the metformin 1000 mg/d group significantly decreased, by a mean of 0.97 kg over the 12 week trial period. Moreover, patients in the metformin at 500 mg/d and 1000 mg/d groups had a significant decrease in body mass index (BMI) after 12 weeks, with the mean decrease being 0.70 and 0.50 kg/m2, respectively. No significant changes were observed in the other metabolic parameters of patients in the three groups.

Conclusions: Our results demonstrated that a low metformin dosage of either 500 mg/d or 1000 mg/d for 12 weeks slightly reduced the BW and BMI of clozapine-treated patients with pre-existing metabolic abnormalities. A longer period of treatment with a larger sample is warranted to determine the factors that influence the metformin treatment response.

Trial registration: ClinicalTrials.gov NCT02751307.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Flowchart of recruitment process—We adopted…
Fig 1. Flowchart of recruitment process—We adopted the LOCF approach.
Patients who continued the intervention for at least 4 weeks were included in the analyses.

References

    1. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–96.
    1. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr., Okasha A, Singh B, et al. (2008) World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 100: 20–38. 10.1016/j.schres.2007.11.033
    1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686–96. 10.1176/ajp.156.11.1686
    1. Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 Suppl 1: 1–93.
    1. Huang MC, Lu ML, Tsai CJ, Chen PY, Chiu CC, Jian DL, et al. (2009) Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 120: 274–80. 10.1111/j.1600-0447.2009.01401.x
    1. Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, et al. (2009) Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 107: 1–12. 10.1016/j.schres.2008.10.011
    1. Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, et al. (2001) Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 50: 856–61. 10.1053/meta.2001.24192
    1. Maayan L, Vakhrusheva J, Correll CU (2010) Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 35: 1520–30. 10.1038/npp.2010.21
    1. Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, et al. (2014) Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 40: 1385–403. 10.1093/schbul/sbu030
    1. Carrizo E, Fernandez V, Connell L, Sandia I, Prieto D, Mogollon J, et al. (2009) Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res 113: 19–26. 10.1016/j.schres.2009.05.007
    1. Hebrani P, Manteghi AA, Behdani F, Hessami E, Rezayat KA, Marvast MN, et al. (2015) Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder. J Res Med Sci 20: 364–71.
    1. Chen CH, Huang MC, Kao CF, Lin SK, Kuo PH, Chiu CC, et al. (2013) Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 74: e424–30. 10.4088/JCP.12m08186
    1. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261–76.
    1. Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, et al. (2008) Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 299: 185–93. 10.1001/jama.2007.56-b
    1. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, et al. (2009) 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374: 1677–86. 10.1016/S0140-6736(09)61457-4
    1. Wu RR, Jin H, Gao K, Twamley EW, Ou JJ, Shao P, et al. (2012) Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 169: 813–21. 10.1176/appi.ajp.2012.11091432
    1. Borruel S, Molto JF, Alpanes M, Fernandez-Duran E, Alvarez-Blasco F, Luque-Ramirez M, et al. (2014) Surrogate markers of visceral adiposity in young adults: waist circumference and body mass index are more accurate than waist hip ratio, model of adipose distribution and visceral adiposity index. PLoS One 9: e114112 10.1371/journal.pone.0114112
    1. Siskind DJ, Leung J, Russell AW, Wysoczanski D, Kisely S (2016) Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis. PLoS One 11: e0156208 10.1371/journal.pone.0156208
    1. Setter SM, Iltz JL, Thams J, Campbell RK (2003) Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther 25: 2991–3026.
    1. Jarskog LF, Hamer RM, Catellier DJ, Stewart DD, Lavange L, Ray N, et al. (2013) Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry 170: 1032–40. 10.1176/appi.ajp.2013.12010127
    1. Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT (2004) The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 256: 1–14. 10.1111/j.1365-2796.2004.01328.x
    1. Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, et al. (2014) Pharmacological Strategies to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull 40: 1385–403. 10.1093/schbul/sbu030
    1. Zheng W, Li XB, Tang YL, Xiang YQ, Wang CY, de Leon J (2015) Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Psychopharmacol 35: 499–509. 10.1097/JCP.0000000000000392
    1. Rosenheck R, Evans D, Herz L, Cramer J, Xu W, Thomas J, et al. (1999) How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. Schizophr Bull 25: 709–19.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다